Kodiak Sciences, Inc. is a US-based pharmaceutical company with a risk rating score of 25.5, signaling a medium risk level. Specializing in novel therapeutics for retinal diseases, Kodiak Sciences is focused on sustainable innovations in the pharmaceutical industry. Their product candidate, KSI-301, offers promising treatment options for neovascular wet AMD patients. Find out more about Kodiak Sciences' ESG initiatives and groundbreaking research in retinal disease treatments.